LeMaitre Vascular, Inc.
NASDAQ:LMATMedical - Instruments & Supplies
+$1.60 today
- Market cap
- $1.73B
- Beta
- 0.52
- P/E (TTM)
- 34.3
- EPS (TTM)
- $2.74
- Dividend yield
- 0.96%
Volume 0.22M
Average 0.26M
LMAT Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
LeMaitre Vascular, Inc.NASDAQ: LMAT
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables dips below year-ago levels
Q1 FY2026 accounts payables of $2.34M (cash outflow) fell 55.5% year over year, behind the +319.4% change in trailing-twelve-month accounts payables. Sequentially, it rose 107.3% from the prior quarter. Over 3 fiscal years it compounded at +86.7% a year.
Context
- Accounts payables amounted to 1.7% of revenue in FY2025, up 1.3 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -55.5% toward the trailing-twelve-month pace of +319.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 4.2M USD
- Year-over-year change
- +638.9%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.2M | +638.9% |
| FY2024 | 2024-12-31 | (779K) | -116.9% |
| FY2023 | 2023-12-31 | 4.6M | +613.0% |
| FY2022 | 2022-12-31 | 645K | +137.2% |
| FY2021 | 2021-12-31 | (1.73M) | — |
Accounts Payables vs competitors
How LMAT compares with its peers on the latest reported figures
- LMAT's LTM Mar 2026 accounts payables of $7.12M is the 7th largest of the 8 companies compared; the peer median is $15.59M.
- Its year-over-year change of +319.4% is the 2nd highest of 8, against a peer median of +24.4%.
- Accounts payables amounts to 2.8% of revenue for LMAT, versus a peer median of 0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $172M | -63.2% | — | 0.8% | |
| LTM Jul 2026 | $113M | -47.4% | -59.6% | 0.3% | |
| LTM Jun 2026 | $16.92M | +451.0% | -38.8% | 1.1% | |
| LTM Jun 2026 | $15.59M | +24.4% | -30.6% | 0.6% | |
| LTM Feb 2026 | $10.94M | +42.4% | — | 3.5% | |
| LTM Mar 2026 | $9.53M | +258.4% | — | 2.1% | |
| LTM Mar 2026 | $7.12M | +319.4% | +86.7% | 2.8% | |
| LTM Sep 2026 | $2.42M | -131.8% | -56.9% | 0.2% | |
| Peer median (excluding LMAT) | $15.59M | +24.4% | -47.9% | 0.8% | |
Competitors are the stored peer set for LMAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 26.91M | 20.64M | 30.11M | 44.04M | 57.73M |
| Depreciation & Amortization | 11.07M | 9.43M | 9.52M | 9.67M | 10.42M |
| Deferred Income Tax | 79K | (182K) | 783K | (451K) | 2.31M |
| Stock-Based Compensation | 3.48M | 4.17M | 5.32M | 6.57M | 7.83M |
| Change in Working Capital | (9.96M) | (13.4M) | (11.25M) | (20.1M) | (1.75M) |
| Accounts Receivables | (818K) | (3.53M) | (3.14M) | (6.42M) | (2.95M) |
| Inventory | (5.49M) | (7.42M) | (9.79M) | (10.57M) | (7.22M) |
| Accounts Payables | (1.73M) | 645K | 4.6M | (779K) | 4.2M |
| Other Working Capital | (1.93M) | (3.1M) | (2.92M) | (2.33M) | 4.22M |
| Other Non-Cash Items | 3.53M | 4.72M | 2.28M | 4.4M | 4.71M |
| Operating Cash Flow | 35.1M | 25.38M | 36.75M | 44.12M | 81.25M |
| Capital Expenditures | (4.88M) | (3.23M) | (7.27M) | (6.96M) | (6.78M) |
| Acquisitions (Net) | 0 | 0 | (899K) | 0 | (1.9M) |
| Purchases of Investments | (59.19M) | (8M) | (16.55M) | (277.94M) | (641.33M) |
| Sales of Investments | 3M | 0 | 0 | 84.78M | 585.07M |
| Other Investing Activities | 0 | 858K | 0 | 0 | 0 |
| Investing Cash Flow | (61.08M) | (10.37M) | (24.72M) | (200.12M) | (64.94M) |
| Debt Repayment | (39M) | 0 | 0 | 169.27M | 0 |
| Common Stock Issued | 63.24M | 3.47M | 6.17M | 6.44M | 6.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (9.34M) | (10.99M) | (12.45M) | (14.38M) | (18.11M) |
| Other Financing Activities | (1.2M) | (1.71M) | (853K) | (3.23M) | (3.25M) |
| Financing Cash Flow | 13.7M | (9.23M) | (7.13M) | 158.1M | (14.54M) |
| Effect of Forex Changes | (637K) | (494K) | 230K | (765K) | 864K |
| Net Change in Cash | (12.91M) | 5.28M | 5.14M | 1.34M | 2.63M |
| Free Cash Flow | 30.22M | 22.15M | 29.49M | 37.16M | 74.47M |
LeMaitre Vascular, Inc.
NASDAQ:LMAT
Intrinsic Alpha fair value
Locked
Current Price
$75.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.